Blog Posts

How Patient Reported Outcomes Can Guide Trial Eligibility – ESMO

ESMO/LinkedIn

Jul 19, 2025, 14:29

How Patient Reported Outcomes Can Guide Trial Eligibility – ESMO

European Society for Medical Oncology shared a post on LinkedIn:

“In the era of Precision Medicine, waiting lists for alteration-matched studies are one of the key challenges in Early Drug Development.

Findings presented at ESMOTATAsia25 highlighted that Patient Reported Outcomes (PROs) may be a valid tool to select fitness for inclusion in a phase I Clinical Trial after 3 months.

Also presented were recommendations from the OPTIMISE-ROR project, which provides foundational guidance for triallists to systematically integrate PROs into dose-finding oncology trials.

Read the full commentary in the ESMO Daily Reporter.”

More posts featuring ESMO on OncoDaily.

cancer Early Drug Development ESMO ESMO Daily Reporter ESMOTATAsia25 European Society for Medical Oncology OncoDaily Oncology OPTIMISE-ROR project Precision Medicine

China Approved DATROWAY (Datopotamab Deruxtecan) for HR-Positive, HER2-Negative Metastatic Breast Cancer

Simon Mooijaart: Patient Perspectives on Antithrombotic Therapy in Advanced Cancer

Hidden Risks: BRCA Mutations and Breast Implants - CancerWorld

Neil Ranasinghe: What’s the Difference Between a Clinician and a Technical Author?

LOCKTAC Molecular Glues Are Changing the Rules of Drug Discovery - Amgen